. 2015 Aug 2;2015:521718. doi: 10.1155/2015/521718

Table 4.

Effects of lisinopril and fosinopril during acquisition trials in Morris water maze test.

Treatment	Latency (sec) to locate the hidden platform on day 1	Latency (sec) to locate the hidden platform on day 4	Mean swim speed (seconds)
Control	44.89 ± 1.42^∗∗	17.24 ± 0.88^∗∗	0.166 ± 0.12^∗∗
Saline control	41.20 ± 1.88^∗∗	16.18 ± 1.71^∗∗	0.172 ± 0.22^∗∗
Scopolamine	53.08 ± 1.56^b	38.42 ± 2.59^b	0.387 ± 0.18^b
Lisinopril (0.225 mg/kg) + scopolamine	50.47 ± 1.45^b	33.64 ± 1.90^b	0.307 ± 0.07^b
Lisinopril (0.45 mg/kg) + scopolamine	46.53 ± 2.08^a	35.93 ± 1.43^b	0.268 ± 0.20^b
Fosinopril (0.90 mg/kg) + scopolamine	47.08 ± 2.58^a	37.42 ± 1.23^b	0.294 ± 0.17^b
Fosinopril (1.80 mg/kg) + scopolamine	49.87 ± 0.89^a	33.10 ± 1.45^∗,a	0.198 ± 0.18^a,∗

Comparisons between control, scopolamine, lisinopril, and fosinopril treated groups during acquisition trials on day 1 and day 4, and on the mean swim speed during the Morris water maze test. Values are mean ± SE, ^∗versus scopolamine (p < 0.05), ^∗∗versus scopolamine (p < 0.001), ^aversus control (p < 0.05), and ^bversus control (p < 0.001).